ArticleInternational journal of molecular sciences2022
Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial.European journal of nutrition · 2025Trial
- Effects of six weeks of hypoxia and hypoxic SIT on oxidative stress and myokine responses in skeletal muscle of high-fat-fed ApoEEuropean journal of applied physiology · 2026Article
- Regulation of follicular helper T cell subset differentiation in health and disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Resveratrol-mediated disruption of the CD73-adenosine-A2AR/A2BR axis induces antitumor activity in colon cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Co-exposure to perchlorate, nitrate, thiocyanate, and per- and polyfluoroalkyl substances (PFAS) mixtures is associated with increased rheumatoid arthritis risk: a population-based cross-sectional study.Clinical rheumatology · 2026Article
- The Role of Nuclear Factor Erythroid 2-Related Factor 2 in the Crosstalk Between Oxidative Stress and M1/M2 Microglial Polarization Following Ischemic Stroke.Molecular neurobiology · 2026Review
- Cumulative adverse social determinants of health and the odds of self-reported rheumatoid arthritis: a national study.Clinical rheumatology · 2026Article
- The interactions between HLA alleles and immune indicators were associated with the risk of rheumatoid arthritis.Clinical rheumatology · 2025Article
- Deciphering the enigma: long noncoding RNAs in disease pathogenesis and therapeutic prospects.Molecular and cellular biochemistry · 2025Review
- Non-FDG PET/CT imaging of inflammatory arthritis.Skeletal radiology · 2025Review
- Identification of Hub Genes and Prediction of Targeted Drugs for Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis.Biochemical genetics · 2024Article
- A proteomics perspective on 2 years of high-intensity training in horses: a pilot study.Scientific reports · 2024Article
- New Highly Selective Antivirals for Chikungunya Virus identified from the Screening of a Drug-Like Compound Library.Current microbiology · 2024Article
- Effects of alloferon and its analogues on reproduction and development of the Tenebrio molitor beetle.Scientific reports · 2024Article
- Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues.Frontiers in pharmacology · 2024Review
- BANNMDA: a computational model for predicting potential microbe-drug associations based on bilinear attention networks and nuclear norm minimization.Frontiers in microbiology · 2024Article
- Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.Pharmacological reports : PR · 2023Review
- Aging-related genes related to the prognosis and the immune microenvironment of acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of vaccines is the most effective and reliable method for the prevention of viral infections. However, research on evaluation of effective therapeutic agents for use in treatment after infection is necessary. Zanamivir was administered through inhalation for treatment of pandemic influenza A/H1N1 in 2009. However, the emergence of drug-resistant strains can occur rapidly. Alloferon, an immunomodulatory drug developed as an NK cell activator, exerts antiviral effects against various viruses, particularly influenza viruses. Therefore, alloferon and zanamivir were administered in combination in an effort to improve the antiviral effect of zanamivir by reducing H1N1 resistance. First, we confirmed that administration of combined treatment would result in effective inhibition of viral proliferation in MDCK and A549 cells infected with H1N1. Production of IL-6 and MIP-1α in these cells and the activity of p38 MAPK and c-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.